JPMorgan Chase & Co. Raises Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $170.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective upped by JPMorgan Chase & Co. from $167.00 to $170.00 in a research note published on Friday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

ASND has been the subject of several other research reports. Cantor Fitzgerald restated an overweight rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, April 18th. Wedbush upped their price objective on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an outperform rating in a research report on Thursday, February 8th. Citigroup lifted their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a buy rating in a research report on Thursday, February 8th. Morgan Stanley restated an equal weight rating and issued a $116.00 price target on shares of Ascendis Pharma A/S in a report on Monday, April 22nd. Finally, Wells Fargo & Company raised their price target on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an overweight rating in a research note on Friday, March 15th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Ascendis Pharma A/S presently has an average rating of Moderate Buy and an average price target of $173.88.

Ascendis Pharma A/S Stock Performance

ASND stock opened at $137.20 on Friday. The firm has a market cap of $7.99 billion, a PE ratio of -14.28 and a beta of 0.54. The firm has a fifty day moving average price of $146.67 and a 200 day moving average price of $128.07. Ascendis Pharma A/S has a fifty-two week low of $83.75 and a fifty-two week high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, topping the consensus estimate of ($2.15) by $0.49. The company had revenue of $148.62 million for the quarter, compared to analysts’ expectations of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 152.68%. On average, equities analysts predict that Ascendis Pharma A/S will post -4.15 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. GAMMA Investing LLC purchased a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth approximately $25,000. Private Ocean LLC bought a new position in Ascendis Pharma A/S in the first quarter worth approximately $36,000. Quadrant Capital Group LLC lifted its holdings in Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after buying an additional 151 shares during the period. EverSource Wealth Advisors LLC boosted its position in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 91 shares in the last quarter. Finally, Signaturefd LLC increased its holdings in shares of Ascendis Pharma A/S by 31.9% in the 3rd quarter. Signaturefd LLC now owns 798 shares of the biotechnology company’s stock valued at $75,000 after acquiring an additional 193 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.